Navigation Links
New muscular dystrophy treatment shows promise in early study led by Children's National
Date:9/17/2013

WASHINGTON, DC A preclinical study led by researchers at Children's National Medical Center has found that a new oral drug shows early promise for the treatment of Duchenne muscular dystrophy (DMD). The results, published in EMBO Molecular Medicine, show that the drug, VBP15, decreases inflammation and protects and strengthens muscle without the harsh side effects linked to current treatments with glucocorticoids such as prednisone.

Duchenne muscular dystrophy results in severe muscle degeneration and affects approximately 180,000 patients worldwide, mostly children. The current standard treatment uses glucocorticoids, but is limited due to serious side effects leading to fragile bones and suppression of both the immune system and growth.

"These findings, while preliminary, are very promising for advancing the treatment of this disease, which causes disability in so many children worldwide," said Eric P. Hoffman, PhD, director of the Center for Genetic Medicine Research at Children's National. "The study also suggests the potential for new strategies in very early treatment, which could further benefit patients."

The Children's National research team also observed that VBP15 inhibits the transcription factor NF-κB, a key cell-signaling molecule found in most cell types that plays a role in inflammation and tissue damage. The team previously found that NF-κB is active in dystrophin-deficient muscle years before the onset of symptoms, suggesting that very early treatment of Duchenne muscular dystrophy patients with VBP15 may prevent or delay the onset of some clinical symptoms.

"VBP15 has an additional property of addressing membrane defects in dystrophic muscle cells," remarked Kanneboyina Nagaraju, DVM, PhD, the lead author of the study, and principal investigator in the Center for Genetic Medicine at Children's National. "It is becoming increasingly clear that membrane integrity and repair are crucial factors not only in muscle, but also in cardiovascular, neurodegenerative, and airway disorders. In-creasing pre-clinical data suggest that VBP15 may show efficacy in these other disorders and in many other indications where steroids are used." Dr. Nagaraju noted.

Initial clinical trials of VBP15 are planned, pending Food and Drug Administration (FDA) review and approval, anticipated in 2014. ReveraGen Biopharma, Inc., the first Children's National private spin-off company, is working closely with Children's National investigators to translate the pre-clinical findings to DMD patients. ReveraGen Biopharma collaborated with NIH/TRND on VBP15, which was selected through a national com-petitive process, one of the few inaugural compounds selected through this novel pro-gram.

"The partnership with NIH and support from many others is illustrative of the importance of private-public partnerships that are essential in expediting the development of orphan disease therapeutics," remarked Edward Connor, MD, CEO, and CMO of ReveraGen Biopharma and Director of Innovation Development at Children's National. "We are optimistic that the new drug will translate well to patients, and are moving this forward as quickly as possible, while assuring safety."


'/>"/>

Contact: Emily Hartman
ehartman@childrensnational.org
202-476-4500
Children's National Medical Center
Source:Eurekalert

Related biology news :

1. Combined therapy could repair and prevent damage in Duchenne muscular dystrophy
2. New drug improves walking performance for Duchenne muscular dystrophy patients
3. Experimental gene therapy treatment for Duchenne muscular dystrophy offers hope for youngster
4. Researchers generate a mutant mouse model useful in the treatment of neuromuscular diseases
5. Scientists discover needle in a haystack for muscular dystrophy patients
6. Tamoxifen ameliorates symptoms of Duchenne muscular dystrophy
7. Stem-cell approach shows promise for Duchenne muscular dystrophy
8. Fred Hutchinson Cancer Research Center partners with GlaxoSmithKline to develop muscular dystrophy therapeutics
9. Another muscular dystrophy mystery solved; MU scientists inch closer to a therapy for patients
10. Protein injection points to muscular dystrophy treatment
11. Researchers discover 2 genetic flaws behind common form of inherited muscular dystrophy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... 21, 2017 Vigilant Solutions , a ... enforcement agencies, announced today the appointment of retired FBI ... public safety business development. Mr. Sheridan brings ... including a focus on the aviation transportation sector, to ... position, Mr. Sheridan served as the Aviation Liaison Agent ...
(Date:3/16/2017)... CeBIT 2017 - Against identity fraud with DERMALOG solutions "Made in ... ... Used combined in one project, multi-biometric solutions provide a crucial contribution against identity fraud. ... Used combined in one project, multi-biometric solutions ... ...
(Date:3/9/2017)... and MOUNTAIN VIEW, Calif. , March ... Made Simple," and 23andMe , the leading personal ... food choices.  Zipongo can now provide customers with personalized ... health goals and biometrics, but also genetic markers impacting ... Zipongo,s personalized food decision support platform uses ...
Breaking Biology News(10 mins):
(Date:4/20/2017)... ... April 20, 2017 , ... Husson University will be celebrating ... body of knowledge during its Eighth Annual Research and Scholarship Day ... Atrium. During the event, undergraduates, graduate students, and faculty members from all of ...
(Date:4/20/2017)... ... April 20, 2017 , ... ... technology applications, announced today that Chief Executive Officer (CEO) Debbie Gustafson has been ... is the global industry association connecting the electronics manufacturing supply chain. The mission ...
(Date:4/20/2017)... Dutch philosopher Koert van Mensvoort - founder of the Next Nature Network ... - has written a ,Letter to Humanity, in support of International ... a slave and victim to its own technology, but to employ technology to ... ... – founder of the Next Nature Network and Fellow of ‘Next Nature’ at ...
(Date:4/19/2017)... ... April 18, 2017 , ... The Vibrating Orifice Aerosol ... for generating monodisperse droplets of known diameters for research applications such as for ... particles by drying monodisperse droplets. , The VOAG requires forcing liquid out ...
Breaking Biology Technology: